A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction



Status:Terminated
Healthy:No
Age Range:18 - Any
Updated:8/12/2018
Start Date:November 2011
End Date:September 2012

Use our guide to learn which trials are right for you!

Patients who present with obstructive jaundice due to a malignant stricture often undergo a
battery of tests for diagnosis, treatment options, and prognosis. An endoscopic retrograde
cholangiopancreatography (ERCP) is often performed with biliary stent placement for symptom
relief as well as brushings for cytology. An endoscopic ultrasound is performed as well for
fine needle aspiration (FNA) of the pancreas to aid in diagnosis. However, since EUS is not
available at many centers, patients often undergo an initial ERCP procedure with stent
placement (which is more widely available) prior to referral for EUS. It has been reported
that biliary stents can disturb EUS visualization due to inflammation, acoustic shadowing,
and pneumobilia which may lessen the accuracy of diagnosis.1 The cytological yield from the
EUS with FNA procedure may also be compromised in patients with biliary stents. As such,
diagnosis and treatment options may be delayed. One retrospective study of 65 subjects showed
a significant difference in the number of correctly staged pancreatic head cancers (mainly T
stage) in patients without stents versus those with biliary stents (85% vs 47%).2 A second
retrospective study concluded that tissue diagnosis is not influenced in patients with stents
placed greater than 24 hours before the EUS; however, patients with stents placed just prior
to the EUS (less than 24 hours) were more likely to have indeterminate results.1 Although the
findings are suggestive, the studies are limited by their retrospective design and these
questions have not yet been addressed in a prospective study.

Both procedures require anesthesia, and when performed sequentially in the same setting, the
duration of anesthesia is prolonged. This is concerning for the patient since complications
may theoretically increase with prolonged anesthesia. However, a retrospective review at a
tertiary referral center showed that combined EUS and ERCP yielded a complication rate no
higher than that of the component procedures.3

At our institution, the current practice is to sequentially perform both EUS and ERCP in the
same setting for patients with suspected malignant biliary obstruction. Typically, EUS-FNA is
performed first, followed by ERCP.

Hypothesis We hypothesize that performing ERCP with biliary stenting immediately prior to
EUS-FNA will decrease the diagnostic yield of EUS-FNA and diminish the ability of EUS to
accurately stage pancreas tumors. Conversely, performing EUS-FNA prior to ERCP will increase
biliary cannulation time and increase success rate.

The objectives of this study are as follows:

1. Determine the diagnostic yield of EUS-FNA (for diagnosis of cancer vs benign process)
when performed either immediately before or after ERCP with biliary stenting (primary
outcome)

2. Determine the ability of EUS to accurately stage pancreatic masses (T and N staging)
when performed either immediately before or after ERCP with biliary stenting (secondary
outcome) in comparison to the gold standard of surgical pathology post resection or in
comparison to CT findings (in those patients who are not surgical candidates)

3. Determine the biliary cannulation time (the time it takes to successfully pass a wire
into the common bile duct from the start of the procedure) and success rate of placing a
biliary stent during ERCP when performed either immediately before or after EUS-FNA
(secondary outcome)


Inclusion Criteria:

- Subjects must be able to review and sign informed consent.

- Subjects must require biliary stenting for the relief of their symptoms as well as FNA
biopsy for proper diagnosis.

- Suspected mass should be located in the head, uncinate, or neck of the pancreas.

Exclusion Criteria:

- Cannot give and sign informed consent.

- The suspected mass is located in the body or tail of the pancreas.

- The patient may be a candidate for palliative biliary stenting (in which a metal stent
would be placed)
We found this trial at
1
site
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials